PRONOUNCE: Randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 10, Issue 1, 2015, Pages 134-142

  Zinner, Ralph G ^a   Obasaju, Coleman K ^b   Spigel, David R ^c   Weaver, Robert W ^d   Beck, J Thaddeus ^e   Waterhouse, David M ^e   Modiano, Manuel R ^f   Hrinczenko, Borys ^g   Nikolinakos, Petros G ^h   Liu, Jingyi ^b   Koustenis, Andrew G ^b   Winfree, Katherine B ^b   Melemed, Symantha A ^b   Guba, Susan C ^b   Ortuzar, Waldo I ^b   Desaiah, Durisala ^b   Treat, Joseph A ^b   Govindan, Ramaswamy ⁱ   Ross, Helen J ^j  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c Division of Medical Oncology   (United States)

^d Hematology Oncology Florida Cancer Specialists   (United States)

^e Hematology Medical Oncology Oncology Heamatology Care Inc   (United States)

^f Arizona Oncology Associates   (United States)

^g MICHIGAN STATE UNIVERSITY   (United States)

^h MEDICAL COLLEGE OF GEORGIA   (United States)

ⁱ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j NONE

more..

Author keywords

Advanced nonsquamous non small cell lung cancer; Bevacizumab; Carboplatin; Combination therapy; Efficacy; Paclitaxel; Pemetrexed; Safety

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; BEVACIZUMAB; CARBOPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; ERLOTINIB; FOLIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PEMETREXED; ANTINEOPLASTIC AGENT; GLUTAMIC ACID DERIVATIVE; GUANINE; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG UTILIZATION; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HOSPITALIZATION; HUMAN; IMMUNOPROPHYLAXIS; INFECTION; INTENTION TO TREAT ANALYSIS; LENGTH OF STAY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOSIS; VITAMIN SUPPLEMENTATION; VOMITING; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PEMETREXED;

EID: 84926419605     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000366     Document Type: Article

References (40)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-594.
3. Obasaju CK, Raju RN, Stinchcombe T, et al. Final results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) + Cb as first-line treatment of patients (pts) with stage IIIB/IV non-small-cell lung cancer (NSCLC). J Clin Oncol 27:15s, 2009 (suppl abstract 8037).
4. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 1993;11:1866-1872.
5. Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 1994;106:861-865.
6. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 1993;342:19-21.
7. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993;85:388-392.
8. Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993;85:384-388.
9. Scagliotti GV, De Marinis F, Rinaldi M, et al Italian Lung Cancer Project. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-4291.
10. Schiller JH, Harrington D, Belani CP, et al Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
11. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
12. Somer RA, Sherman E, Langer CJ. Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599. Clin Lung Cancer 2008;9:102-105.
13. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
14. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
15. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
16. Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31:2895-2902.
17. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009;14:253-263.
18. Peterson P, Park K, Fossella F, et al. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs. docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2007;2:s851.
19. Zinner RG, Fossella FV, Gladish GW, et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 2005;104:2449-2456.
20. Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 2005;11(2 Pt 1):690-696.
21. Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31:4349-4357.
22. Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001;19:1336-1343.
23. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002;20:1335-1343.
24. Socinski MA, Stinchcombe TE. Duration of first-line chemotherapy in advanced non small-cell lung cancer: less is more in the era of effective subsequent therapies. J Clin Oncol 2007;25:5155-5157.
25. Lustberg MB, Edelman MJ. Optimal duration of chemotherapy in advanced non-small cell lung cancer. Curr Treat Options Oncol 2007;8:38-46.
26. Pujol JL, Paul S, Chouaki N, et al. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis. J Thorac Oncol 2007;2:397-401.
27. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
28. [NCI] National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE), 2006; available from http://ctep.cancer. gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf;Internet; accessed 22 Apr. 2014.
29. Zinner RG, Saxman SB, Peng G, Monberg MJ, Ortuzar WI. Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histology. Clin Lung Cancer 2010;11:352-357.
30. Dubey S, Brown RL, Esmond SL, Bowers BJ, Healy JM, Schiller JH. Patient preferences in choosing chemotherapy regimens for advanced non-small cell lung cancer. J Support Oncol 2005;3:149-154.
31. Rodrigues-Pereira J, Kim JH, Magallanes M, et al. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer. J Thorac Oncol 2011;6:1907-1914.
32. Scagliotti GV, Park K, Patil S, et al. Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study. Eur J Cancer 2009;45:2298-2303.
33. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-1234.
34. Ramalingam SS, Dahlberg SE, Langer CJ, et al Eastern Cooperative Oncology Group. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008;26:60-65.
35. Langer CJ, Socinski MA, Patel JD, et al. Efficacy and safety of paclitaxel and carboplatin with bevacizumab for the first-line treatment of patients with nonsquamous non-small cell lung cancer (NSCLC): analyses based on age in the phase 3 PointBreak and E4599 trials [IASLC abstract MO06.12]. J Thorac Oncol 2013;8(suppl 2):S291.
36. Wong YN, Egleston BL, Sachdeva K, et al. Cancer patients' trade-offs among efficacy, toxicity, and out-of-pocket cost in the curative and noncurative setting. Med Care 2013;51:838-845.
37. Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 2013;18:381-390.
38. Zafar SY, Abernethy AP. Financial toxicity, part I: a new name for a growing problem; Available at: http://www.cancernetwork.com/practice-policy/financial-toxicity-part-i-new-name-growing-problem. Accessed April 22, 2014.
39. Zafar SY, Abernethy AP. Financial toxicity, part II: how can we help with the burden of treatment-related costs? Available at: http://www.cancernetwork.com/practice-policy/financial-toxicity-part-ii-how-can-we-helpburden-treatment-related-costs. Accessed April 22, 2014.
40. Graham CN, Knox H, Winfree KB, et al. Cost-minimization analysis of pemetrexed/carboplatin with maintenance pemetrexed (PemC) versus paclitaxel/carboplatin/bevacizumab with maintenance bevacizumab (PCB) in nonsquamous non-small cell lung cancer (NS-NSCLC). ASCO Quality Care Symposium 2013 (abstr 263).